Mapreg

Executive Summary

Mapreg is a preclinical French biotechnology company pioneering first-in-class small molecule 'neuroplastogens' for central nervous system disorders. Founded in 2007 and based in Paris, the company leverages foundational discoveries in neurosteroids to develop therapies that internally re-drive neuroplasticity, aiming to repair neuronal function in conditions such as depression, Alzheimer's, and other CNS diseases. With a strong scientific foundation from renowned founders, Mapreg is positioned to address significant unmet medical needs by targeting the underlying neurobiological mechanisms of these disorders. As a private, preclinical-stage company, Mapreg has not yet disclosed significant funding or partnerships but operates in a competitive landscape where innovation in neuroplasticity is gaining interest. The company's progress will depend on advancing its lead candidates through preclinical development and securing strategic collaborations or financing to move toward clinical trials.

Upcoming Catalysts (preview)

• Q3 2026Lead candidate IND-enabling studies completion60% success
• Q4 2026Series A or seed funding round announcement50% success
• Q2 2026Preclinical proof-of-concept data publication70% success